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Abstract
Background: Acute liver injury (ALI) induced by paracetamol overdose is a well known cause of emergency hospital
admission and death. However, there is debate regarding the risk of ALI after therapeutic dosages of the drug.
The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to
therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case.
Methods: Based on the evaluation of prospectively gathered cases of ALI with detailed clinical information, thirty-
two cases of ALI in non-alcoholic patients exposed to therapeutic doses of paracetamol were identified. Two
authors assessed all drug exposures by using the CIOMS/RUCAM scale. Each case was classified into one of five
categories based on the causality score for paracetamol.
Results: In four cases the role of paracetamol was judged to be unrelated, in two unlikely, and these were
excluded from evaluation. In seven of the remaining 26 cases, the RUCAM score associated with paracetamol was
higher than that associated with other concomitant medications. The estimated incidence of ALI related to the use
of paracetamol in therapeutic dosages was 0.4 per million inhabitants older than 15 years of age and per year
(99%CI, 0.2-0.8) and of 10 per million paracetamol users-year (95% CI 4.3-19.4).
Conclusions: Our results indicate that paracetamol in therapeutic dosages may be considered in the causality
assessment in non-alcoholic patients with liver injury, even if the estimated incidence of ALI related to paracetamol
appears to be low.
Background
Paracetamol is the most important pharmacological
cause of acute liver failure (ALF) [1-5] and is the primary
cause of overdose in the UK, USA and Scandinavian
countries. It is thought to be safe in recommended doses,
up to 4 g per day in adults. The public health impact of a
paracetamol overdose has been evaluated in several epi-
demiological studies [1-3,5,6]. In a multicentric survey of
ALF including hospitals attending approximately half the
Spanish population, paracetamol was considered to be
the cause of ALF in only 2.6% of 267 cases identified
between 1992 and 2000, and the estimated incidence of
ALF during the study period was of 1.4 cases per million
inhabitants per year [7]. In contrast, liver injury after
therapeutic dosages appears to be highly unusual and the
mechanism accepted for the overdose liver injury has in
fact been under discussion [8-10].
In a clinical trial in healthy volunteers who received 4
g of paracetamol daily, significant increases in alanine
aminotransferase (ALT) were recorded [11]. The clinical
significance of these results is unknown. In an epide-
miological study a relative risk (RR) of acute liver injury
(ALI) associated with paracetamol in therapeutic
dosages, of 7.0 (99% CI 3.3-13.9) with an incidence rate
of 2.4 cases per 100,000 person-years of exposure, was
estimated [12].
The aim is to describe the characteristics of patients
admitted to hospital with jaundice who had previous
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exposure to therapeutic dosages of paracetamol. An
assessment of the causality role of paracetamol was per-
formed in each case.
Methods
Case selection
Between January 1993 and December 1999, 32 cases of
ALI in patients exposed to therapeutic dosages of para-
cetamol (4 g per day or less) were assembled as part of
a multicentric prospective epidemiological study, with a
systematic ascertainment of the incident cases of ALI,
irrespective of the suspected cause [12].
A collaborating network including 12 hospitals cover-
ing a population of 2.7 × 106 inhabitants of 15 years of
age or older was set up. To avoid any selection bias the
patients were selected on the basis of their condition,
rather than on the basis of suspected exposures. Cases
of ALI were defined as jaundice with a total bilirubin
level of ≥ 3 mg/dl and an acute increase in ALT of at
least five times the upper limit of the normal range and/
or an increase in alkaline phosphatase (AP) of at least
twice the upper limit of the normal range. Patients with
alcohol consumption greater than 50 g per day and/or
with other possible causes of liver injury were excluded
(the principal causes were serologically proven viral
hepatitis, alcoholic liver disease, processes causing
obstruction of bile flow and drug overdoses). The pat-
tern of ALI was classified as hepatocellular, cholestatic
or mixed, according to the International Consensus
Meeting designations of ALI [13].
The patients were interviewed, after informed consent
was given, using a structured questionnaire covering
their past medical history, clinical course of the present
condition, and detailed information on the use of medi-
cines and exposure to environmental toxins in the pre-
vious three months. Clinical and laboratory data were
also recorded.
As described, this was a population-based study, and
thus allowed us to estimate the incidence of ALI related
to paracetamol based on the cases defined as probably
or possibly related to paracetamol exposure. The inci-
dence on paracetamol users was estimated on the basis
of drug consumption data. Confidence limits at 95%
were used to obtain an approach to the precision of the
estimated incidence.
The methods have been described in detail elsewhere
[14].
Causality assessment
Two authors assessed all the drugs taken by each patient
in the three-month period before laboratory diagnosis in
each case using the CIOMS/RUCAM scale [15]. At pre-
sent the RUCAM algorithm is widely used for causality
assessment of hepatotoxicity [16-19].
The method provides a score for each individual drug
taken by a patient with ALI. The score allows the classi-
fication of each drug into five categories: “highly prob-
able” (score > 8), “probable” (6 - 8), “possible” (3 - 5),
“unlikely” (1 - 2) and “excluded” (< or = 0). When the
time of onset is clinically incompatible, the drug is clas-
sified as “unrelated”.
Each case was classified into one of five categories
based on the score related to the causal role of
paracetamol.
Details on the application of the seven items of the
RUCAM scale were agreed on before the evaluation.
Non-pharmacological possible causes of ALI were not
present, because of stringent selection criteria (see
Methods above). There were no cases reexposed to
paracetamol after liver damage occurred. The cases pre-
sented in the results are those that paracetamol had a
higher RUCAM score than the concomitant drugs.
In the 90’s it was not compulsory (as it is nowadays)
to have the approval of an appropriate ethics committee
for observational studies in Spain. However, the study
was approved by: CIRIT (Comisionat per a Universitats
i Recerca, Generalitat de Catalunya) Accions Mobilitza-
dores (1995XT 00030) (Committee for Universities and
Research, Government of Catalonia) Mobilization
Resources, 1995XT 00030).
Results
Up to December 31 1999, total follow up was 17,616,592
person-years and 126 patients fulfilling the inclusion cri-
teria of ALI were identified. Drug exposures among
these patients with ALI and comparative risks associated
with various commonly used drugs have been reported
on [12,14].
The RUCAM scale was applied to 32 cases exposed
to paracetamol. In four cases paracetamol exposure
started on the day the first symptoms of ALI (fever,
abdominal pain, marked weakness, skin rash and/or
pruritus, jaundice or choluria) appeared, and they were
therefore classified as unrelated to paracetamol. In two
cases the RUCAM score for paracetamol was < or = 2
and they were classified as unlikely. Of the remaining
26 cases, the score for paracetamol was higher than
that for other concomitant drugs (7 cases). In 19 addi-
tional cases that took drugs that are known to be
hepatotoxic agents, these drugs scored equal or higher
than paracetamol. The different scores between the
cases classified as “probable” and those classified as
“possible” were mainly due to the differences in three
items: time to onset, the course of the reaction after
cessation of the drug, and previous information on the
association between paracetamol exposure and liver
injury, which in one case with a mixed pattern scored
one point less.
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Several features for the 7 cases (4 probable and 3 pos-
sible) with a paracetamol score higher than that of con-
comitant drugs are provided in table 1
Six cases were female and the median age was 35
(range 18-85).
The median daily dose of paracetamol was 650 mg
(range 650-3,250). The median duration of the exposure
period, i.e. the period between the first and the last day
of use was 10 days (range 1-77) in five patients. The
other two patients had taken the drug for at least one
year. The median alcohol consumption was 13.43 g per
day (range 0-42.67).
In six patients the pattern of liver injury was hepato-
cellular. Five cases showed symptoms of hypersensitivity
(fever, rash, eosinophilia, thrombocytopenia or arthral-
gia). All cases except one were taking other drugs.
Hypersensitivity reactions have been described for meta-
mizol, dextromethorphan, indapamide, indomethacin,
corticosteroids, metoclopramide, bisacodyl, budesonide,
carbocysteine, ambroxol, benzocaine, chlorhexidine [20].
After 6 months of follow-up, five patients recovered
completely (median of 3.7 months; range 1.27-21.8), one
had undergone a liver transplant, while another had not
fully recovered.
The estimated population incidence of ALI related to
the use of paracetamol at therapeutic dosages based on
the 7 cases classified as probable or possible was 0.4 per
106 inhabitants older than 15 years of age and per year
(95%CI, 0.2-0.8) and of 10 per 106 paracetamol users-
year (95% CI 4.3-19.4).
Discussion
To our knowledge, this is the largest prospective series
describing cases of severe ALI in patients exposed to
therapeutic dosages of paracetamol that have ever been
published.
In 7 out of 26 patients with ALI previously exposed to
paracetamol, the RUCAM causality algorithm score for
the drug was higher than that for other concomitant
medications. Out of these seven cases the association
with paracetamol was classified as probable in four of
these cases. Six of these seven patients had a hepatocel-
lular pattern of liver injury which is typical of paraceta-
mol overdose and six were female [21]. Of note, most of
these cases had accompanying hypersensitivity
symptoms.
Although paracetamol was classified as a probable or
possible cause of ALI in the 19 remaining cases, these
patients had also taken other known hepatotoxic drugs
which achieved higher scores than that of paracetamol.
However, a contributory role of paracetamol in liver
injury in these cases cannot be ruled out [22].
Paracetamol in high single doses (typically 15 g or
more) causes liver injury through a toxic metabolite,
NAPQI (N-acetyl-p-benzoquinone imine). Alcohol con-
sumption and possibly starvation induce cytocrome P-
450 and therefore increase NAPQI synthesis. These fac-
tors also contribute to glutathione depletion, [23,24]
thus enhancing paracetamol hepatotoxicity. Therefore,
heavy drinkers would be at high risk of liver toxicity
with paracetamol taken in relatively high doses
[8,9,21,25-27]. Acute liver failure has also been reported
after doses up to 5 g per day, particularly in alcoholic
patients, as well as in fasting patients and patients with
underlying liver disease [8,28-30]. Those seven cases
reported low alcohol consumption, except case number
1. This patient underwent a liver transplant, and we
cannot rule out that paracetamol probably enhanced
alcohol toxicity. No patient turned up with a wasting
disease or with signs of starvation.
A systematic review of the occurrence of acute liver
failure associated with paracetamol in therapeutic
dosages reported a median duration of exposure of 6
days in the review of RCTs and 10 days in the retro-
spective studies. These figures compare well with the
median duration of the exposure among five cases with
short use of paracetamol (10 days). In addition, 26% of
the patients in the systematic review had taken another
drug with a causality score higher than that of paraceta-
mol, [10] compared to 73% in our series. However, it
should be pointed out that our study was specially
designed to collect drug exposures including over the
counter drugs and herbs in a rigorous way.
Liver injury after therapeutic dosages of paracetamol
has been described in several case reports, but the
patients had concurrent potentially contributing condi-
tions, such as asymptomatic HIV infection, hepatitis B
or hepatitis C virus infection, heavy alcohol consump-
tion (more than 50 g per day), and/or fasting and nutri-
tional impairment [31-36]. In our study patients with
these conditions were excluded. In a randomized con-
trolled trial, 31% - 44% of healthy young participants
experienced an ALT level greater than 3 times the
upper limit of the normal range (ULN) and more than
19% of participants experienced ALT more than five
times the ULN during treatment with paracetamol at a
dose of 4 g per day for 14 days, although none devel-
oped symptoms or laboratory evidence of hepatic failure
[11].
Hypersensitivity to paracetamol is rare, although a few
cases of paracetamol-induced idiosyncratic hepatic
injury [37-39] have been described. One case recurred
on drug rechallenge, and showed symptoms of hyper-
sensitivity [31]. Paracetamol seldom produces allergic
skin reactions or respiratory symptoms, [40,41] and ana-
phylactic shock also occurs very rarely [42]. Thrombocy-
topenia related to paracetamol has also been described
even though in one case it can be explained by the use
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Table 1 Patients classified as a probable or possible based on paracetamol score (RUCAM algorithm)
Use of paracetamol
Case Sex/
Age
Alcohol
use
(g/d)
ALT/
AP
Bili Pattern
of ALI
Hypersensitivity Outcome Indication Daily dose
(mg)
Pattern of use RUCAM
Score
Concomitant drugs RUCAM
Score
Probable (6 to 8)
1 F/58 43 15.85/
1.74
1.36 HC No Tx Osteoarthritis 650 Once a week for years till day
before ALI.
8
Dexchlorpheniramine 7
2 F/82 0 15.32/
1.95
10.41 HC Thrombocytopenia Recovered Cold 650 Daily for 10 days before ALI. 7
Metamizol 6
Dextromethorphan 6
Chlorphenamine 6
Indapamide 6
Indomethacin 6
Tocopherol 5
3 F/85 0.5 22.21/
1.27
12.32 HC Arthralgia,
thrombocytopenia
Not
recovered
Osteoarthritis 1950 Daily for 22 days before ALI. 7
Corticosteroids 6
4 F/25 24 383.33/
2.35
3.64 HC Eosinophilia Recovered Cephalea 3250 Daily for 2 days before ALI. 7
Metoclopramide 6
Bisacodyl 6
Possible (3 to 5)
5 M/18 13 5.27/
1.24
5.88 M Fever Recovered Cephalea 650 1 day, 11 days before ALI. 5
Budesonide 3
6 F/23 13 50.23/
2.16
9.23 HC Fever, rash Recovered Cephalea 500 1 day, 2 months before ALI. 4
Fever 1950 1 day, 3 months before ALI.
Fever 1950 3 days, between day 21 and day
13 before ALI.
Carbocysteine 3
Ambroxol 3
Benzocaine 3
Chlorhexidine 3
7 F/35 20 61.10/
0.64
22.43 HC No Recovered Dysmenorrhea 650 Once a month for last year till 11
days before ALI.
3 No -
Alcohol use is expressed as a mean in grams per day in the last year; ALT, alanine aminotransferase and AP, alkaline phosphastase and Bili, bilirubin, expressed in times the upper limit of normal values; outcome at
6 months of follow-up; ALI, acute liver injury; HC, hepatocellular; M, mixed; Tx, liver transplantation.
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of other drugs (non steroidal anti inflammatory drugs)
taken by the patient [43]. In our series, three of the four
patients with the highest causality scores for paraceta-
mol had symptoms of hypersensitivity, suggesting that
an immunological mechanism could be involved. This
mechanism may explain the presence of ALI in cases
with a short period of exposure.
The population-based incidence of ALI related to
paracetamol at therapeutic dosages is low, less than one
case per 106 inhabitants per year in our study area.
Paracetamol use at therapeutic dosages may be consid-
ered safe enough regarding its potential liver toxicity.
However, considering the high amount of paracetamol
consumption [44] in developed countries it is important
to take into account this data in terms of its public
health impact.
Our study contributes to completing the information
about drug-induced liver injury, especially about liver
toxicity and paracetamol at therapeutic dosages, a topic
that has not been studied from a prospective design up
to now as far as we know. In fact its incidence is
unknown and we provide an estimation where paraceta-
mol is one of the most widely used analgesics. There
has also been some controversy about its importance
since the publication of a RCT [11] where the increase
in transaminases seems more frequent than had pre-
viously been thought.
Our study has several strengths. Stringent clinical
inclusion criteria were applied, case ascertainment was
prospective, and the case definition depended on strict
clinical criteria rather than on exposure to any particular
drug. Additionally, intensive systematic ascertainment of
all patients fulfilling the study criteria was performed
within the study area. The exclusion of patients with
alcohol consumption greater than 50 g per day and/or
with other possible causes of liver injury (the principal
causes were serologically proven viral hepatitis, alcoholic
liver disease, processes causing obstruction of bile flow
and drug overdoses) allows us to focus on a more
selected population where other causes of ALI have
been discarded. In order to avoid selection bias, only
serious forms of acute liver disease, usually with jaun-
dice, were included. In addition, details on previous use
of medicines (including over the counter drugs and
herbs) and alcohol consumption were carefully recorded
by asking patients using a detailed structured question-
naire about symptoms, specific indications that covered
the use of medicines most frequently associated with
liver disease, and by showing them pictures of the major
medications of interest. Patients with other known
causes of liver disease were excluded. A standardized
method of causality assessment was used which may
overcome some of the disadvantages of expert opinions
in causality assessment of drug reactions.
Our study also has several limitations. Causality
assessment was based on algorithms which are relatively
simple to apply but where the weighting of each criter-
ion can be somewhat arbitrary. Even though the
RUCAM scale is considered at present as the best
method for assessing causality in drug-induced liver dis-
ease, [45,46] the scale has some limitations, such as the
poor definition of the items to be answered and the
scarce diagnostic capability when two drugs are admi-
nistered at the same time. This algorithm awards higher
scores to the known hepatotoxic medications, and there-
fore it may tend to underestimate the causative role of
any medication previously unknown to be hepatotoxic.
However, not only recently marketed but also old drugs
still not incriminated in hepatotoxicity could be to
blame [45]. On the other hand, the RUCAM scale does
not take into account symptoms of hypersensitivity,
while nearly one third of acute hepatic drug reactions
are mediated by immunoallergic mechanisms. In addi-
tion, very late onset of ALI is awarded lower scores,
while several drugs are known to cause liver injury after
latency periods of more than 90 days [47]. Finally, the
algorithm does not take into account the indication of
the suspected medication, which in turn may actually
have been prescribed to alleviate early symptoms of liver
disease.
Conclusions
The data from the present case series using detailed
clinical and laboratory information indicate that parace-
tamol in therapeutic dosages may be considered a factor
in the causality assessment in patients with liver injury
in non-alcoholic individuals,(even if the estimated inci-
dence appears to be low). However, the diagnosis of
acute liver injury and the causality assessment to a parti-
cular drug remains a difficult task. Liver injury shows a
hepatocellular pattern and concomitant symptoms of
hypersensitivity in a proportion of cases suggest that the
mechanism could be immune mediated. The threshold
dose for paracetamol toxicity may vary among indivi-
duals, and it may depend on genetic as well as environ-
mental factors. Further studies of the intrinsic
mechanisms of hepatotoxicity and the research in bio-
markers are needed for a better clinical management of
those patients. The estimated population incidence and
the incidence in paracetamol users were low and parace-
tamol use at therapeutic dosages may be considered safe
enough regarding its potential liver toxicity.
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